

# Patient-Alert-Card

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA

## TREATMENT WITH KINERET® “Anakinra”

Patient's name:

---

Caregiver's name (for children):

---

Patient's dose:

---

Physician's name and phone number:

---

# Important safety information regarding Still's disease

Macrophage activation syndrome (MAS) is a serious complication of Still's disease. Left untreated MAS can be life threatening. The risk for developing MAS is increased if you have an infection or if your Still's disease symptoms are poorly controlled. Symptoms of MAS can be e.g. persistent high fever, swelling of lymph nodes, and persistent rash.

Kineret® (anakinra) can increase the risk for a serious infection. Symptoms might be persistent high fever, shivers, cough, headache, and redness and tenderness of the skin. Also, persistent low-grade fever, weight loss, and persistent cough can be signs of an infection.

If you develop signs of an infection or worsening of your Still's disease symptoms you should contact your health care provider as soon as possible.

To report adverse events or safety concerns, contact:

**The National Pharmacovigilance Centre (NPC) Saudi Food and Drug Authority (SFDA):**

- SFDA call center: 19999
- E-mail: [npc.drug@sfd.gov.sa](mailto:npc.drug@sfd.gov.sa)
- Website: <http://ade.sfda.gov.sa/>

**Swedish Orphan Biovitrum AB (publ):**

- Email: [pv-ksa@sobi.com](mailto:pv-ksa@sobi.com)

